On this week’s installment of Breaking Health, Host Steve Krupa – CEO of the Psilos Group – dives into the intriguing story behind SolveBio, a company working to disrupt precision medicine.In this interview, Mark Kaganovich, PhD, CEO, and co-founder, discusses the benefits of SolveBio’s innovative data layer – called the “Genomic Intelligence Platform” – aimed at enabling pharma, biotech, and diagnostic organizations to effectively interact with genomic information.Founded in 2013 by graduate school classmates David Caplan, David Gross, and Kaganovich, SolveBio recognizes that isolated DNA sequencing technology has become increasingly essential in medicine and health care. But the process lacks accessible reference data that compares and cross references results from similar clinical trials, studies, and cases that may help decided company strategy or patient care. Kaganovich says the lack of context in genomics studies can sometimes be “mind boggling.”“This hasn’t really fully played out yet, but you’ll have people that make life-altering decisions based on a diagnostic report, and that report, where is the reference data for that? How do you know if you have a pathogenic variance or a benign variance?” Kaganovich asks. “It comes from some reference data set somewhere that probably some grad student contributed to some FTP site, and that kind of sat there. And then it was parsed out by a bioinformatician. It was normalized and some kind of quality control was done. But in the end, it comes from research often, or people don’t even know where it comes from. And to me, that’s kind of scary.”Where is SolveBio now? Dive with us into the episode here to learn in more detail about what the wider applications to SolveBio's mission could mean for health care tech and population care, and how its in-depth knowledge hub has already helped well-known customers.